Nivolumab/Relatlimab Yields Long-Lasting Activity in Pretreated Melanoma
Source: Cancer Network, March 2023
Nivolumab (Opdivo) plus relatlimab (Opdualag) produced a manageable safety profile and long-lasting clinical activity in patients with advanced melanoma that has progressed following prior treatment with anti–PD-L1 regimens, according to findings from the phase 1/2a RELATIVITY-047 trial (NCT01968109).
The objective response rate (ORR) by blinded central independent review (BICR) was 12.0% (95% CI, 8.8%-15.8%) for a cohort of patients who received only 1 prior line of anti–PD-L1 therapy (D1) and 9.2% (95% CI, 5.2%-14.7%) in a cohort of patients who received 1 or more lines of anti–PD-L1 therapy (D2). Additionally, the median duration of response (DOR) was not reached (NR; 95% CI, 12.9-NR) in D1 and 12.8 months (95% CI, 6.9-12.9) in D2.
“Response rates appeared to be enriched among patients with tumors expressing PD-L1 or LAG-3; however, responses were observed regardless of PD-L1 and LAG-3 expression (1% cutoff),” the study authors stated. Additionally, the results suggested “that LAG-3 and PD-L1 may not be appropriate as sole markers for treatment selection.”